Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $93.3 million.

  • Cytek Biosciences' Cash & Equivalents fell 4251.57% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year decrease of 4251.57%. This contributed to the annual value of $98.7 million for FY2024, which is 4099.43% down from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Cash & Equivalents is $93.3 million, which was down 4251.57% from $75.5 million recorded in Q2 2025.
  • Cytek Biosciences' Cash & Equivalents' 5-year high stood at $376.8 million during Q3 2021, with a 5-year trough of $75.5 million in Q2 2025.
  • Its 5-year average for Cash & Equivalents is $214.7 million, with a median of $173.3 million in 2024.
  • As far as peak fluctuations go, Cytek Biosciences' Cash & Equivalents surged by 12067.17% in 2021, and later tumbled by 5757.44% in 2025.
  • Over the past 5 years, Cytek Biosciences' Cash & Equivalents (Quarter) stood at $364.6 million in 2021, then fell by 18.65% to $296.6 million in 2022, then plummeted by 43.59% to $167.3 million in 2023, then tumbled by 40.99% to $98.7 million in 2024, then dropped by 5.51% to $93.3 million in 2025.
  • Its Cash & Equivalents stands at $93.3 million for Q3 2025, versus $75.5 million for Q2 2025 and $95.3 million for Q1 2025.